Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Developmental therapeutics

1164 - NOX66 plus carboplatin - a phase 1 signalling study (LBA2)


18 Nov 2017


Developmental therapeutics


Cytotoxic Therapy;  Clinical Research


Graham Kelly


Annals of Oncology (2017) 28 (suppl_10): x186-x195. 10.1093/annonc/mdx729


I. Minns, G. Kelly, M. Messina

Author affiliations

  • Clinical Development And Medical Affairs, Noxopharm Limited, 2074 - Sydney/AU


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1164


The isoflavone idronoxil has been shown to be an effective chemosensitizing agent across various tumour cell lines, with its selective inhibition of tumour specific NADH oxidase (ENOX2) identifying it as a prime drug candidate. Clinical trials of oral idronoxil, however, showed no clinical efficacy, due to rapid and complete Phase 2 metabolism and elimination of idronoxil. NOX66 is a formulation of idronoxil within a fatty acid base which, when delivered rectally, may protect idronoxil from complete Phase 2 metabolism and rapid elimination. Here we will present interim results from the first human study, discussing the safety of NOX66 at two doses and inital efficacy findings of low dose NOX66 in combination with low dose carboplatin.


Patients (16) with end stage, refactory solid tumours, and no further therapy options available, were allocated to one of two treatment cohorts, receiving NOX66 at a dose of 400mg or 800mg of idronoxil daily. Part 1: Patients receive NOX66 for 14 consecutive days as monotherapy, to assess idronoxil levels and safety of monotherapy. Following saftey assessment, each patient through to Part 2. Part 2: Patients receive NOX66 in combination with carboplatin for up to 6 treatment cycles of 28 days. NOX66 is administered on days 1-7 of each cycle, with carboplatin on Day 2. Carboplatin is initially administered at low dose (AUC4), increasing to standard dose (AUC6) following the completion of 3 cycles. Ongoing safety are conducted throughout the study, with measures to identify efficacy signals (CT scan, ECOG) performed at baseline and after Cycles 3 and 6.


Recruitment for the study was completed in September 2017. As of October 2017, there have been no adverse events associated with NOX66 that have led to study discontinuation. Cohort 1, Low dose (AUC4) carboplatin treatment with NOX66 (400mg) has completed, with 5 of the 8 patients reporting Stable Disease and one patient reporting Disease Progression. Two patients could not be evaulated (1 withdrawal, 1 non-evaluable lesion).


NOX66 in combination with carboplatin is well tolerated, with efficacy data for patients receiving low dose-low dose combination therapy providing evidence to suggest that NOX66 may sensitize end stage solid tumours to chemotherapy.

Clinical trial identification

Protocol NOX66-001A; NCT02941523

Legal entity responsible for the study

Noxopharm Limited


Noxopharm Limited


G. Kelly, I. Minns: Employee of the sponsor organization, Noxopharm Limited. M. Messina: Employee and shareholder of the sponsor company, Noxopharm Limited.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.